PMID- 27524468
OWN - NLM
STAT- MEDLINE
DCOM- 20171205
LR  - 20210109
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 82
IP  - 6
DP  - 2016 Dec
TI  - Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and 
      angioedema in the UK Clinical Practice Research Datalink.
PG  - 1647-1659
LID - 10.1111/bcp.13090 [doi]
AB  - AIM: The aim of the present study was to describe the occurrence and determinants 
      of angiotensin-converting enzyme (ACE) inhibitor (ACEI) intolerance and 
      angioedema (AE) among patients initiating ACEI therapy in a real-world primary 
      care population. METHODS: Two nested case-control studies were conducted in a 
      cohort of 276 977 patients aged >/=45 years initiating ACEIs from 2007 to 2014 in 
      the UK Clinical Practice Research Datalink (CPRD). Cases of AE occurring for the 
      first time during ACEI therapy (n = 416) were matched with AE-free controls (n = 
      4335) on the duration of ACEI treatment. Documented switches to angiotensin-II 
      receptor blockers in the prescription records were used to identify 
      ACEI-intolerance cases (n = 24 709), and these were matched with continuous ACEI 
      users (n = 84 238) on the duration of ACEI therapy. Conditional logistic 
      regression was used to assess the associations of demographic factors, 
      comorbidities and comedication with AE and ACEI intolerance. RESULTS: AE during 
      ACEI therapy was associated with age over 65 years [odds ratio (OR) 1.36, 95% 
      confidence interval (CI) 1.07, 1.73], history of allergy (OR 1.53, 95% CI 1.19, 
      1.96), use of calcium channel blockers (OR 1.57, 95% CI 1.23; 2.01), use of 
      antihistamines (OR 21.25, 95% CI 16.44, 27.46) and use of systemic 
      corticosteroids (OR 4.52, 95% CI 3.26, 6.27). ACEI intolerance was significantly 
      associated with more comorbidities and comedication compared with AE, including 
      allergy (OR 2.02, 95% CI 1.96, 2.09), use of antiasthmatic drugs (OR 1.51, 95% CI 
      1.42, 1.61) and use of antihistamines (OR 1.53, 95% CI 1.43, 1.63). CONCLUSIONS: 
      Among ACEI users developing AE or ACEI intolerance, several comorbidities and 
      comedication classes were significantly more prevalent compared with ACEI users 
      not developing these adverse reactions.
CI  - (c) 2016 The British Pharmacological Society.
FAU - Mahmoudpour, Seyed Hamidreza
AU  - Mahmoudpour SH
AD  - Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of 
      Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The 
      Netherlands.
FAU - Baranova, Ekaterina Vitalievna
AU  - Baranova EV
AD  - Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of 
      Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The 
      Netherlands.
FAU - Souverein, Patrick C
AU  - Souverein PC
AD  - Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of 
      Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The 
      Netherlands.
FAU - Asselbergs, Folkert W
AU  - Asselbergs FW
AD  - Department of Cardiology, Division Heart and Lungs, University Medical Centre 
      Utrecht, Utrecht, The Netherlands.
AD  - Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, 
      Utrecht, The Netherlands.
AD  - Institute of Cardiovascular Science, faculty of Population Health Sciences, 
      University College London, London, UK.
FAU - de Boer, Anthonius
AU  - de Boer A
AD  - Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of 
      Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The 
      Netherlands.
FAU - Maitland-van der Zee, Anke Hilse
AU  - Maitland-van der Zee AH
AD  - Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of 
      Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The 
      Netherlands.
CN  - PREDICTION-ADR consortium
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161004
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Aged
MH  - Angioedema/*chemically induced/*epidemiology
MH  - Angiotensin Receptor Antagonists/administration & dosage/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*adverse 
      effects/therapeutic use
MH  - Antihypertensive Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Drug Prescriptions/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Prevalence
MH  - Risk Factors
MH  - Sex Factors
MH  - United Kingdom
PMC - PMC5099558
OTO - NOTNLM
OT  - ACE inhibitor intolerance
OT  - ACE inhibitors
OT  - angioedema
OT  - angiotensin II receptor blockers
OT  - case-control studies
OT  - drug-related side effects and adverse reactions
EDAT- 2016/08/16 06:00
MHDA- 2017/12/06 06:00
PMCR- 2017/12/01
CRDT- 2016/08/16 06:00
PHST- 2016/02/29 00:00 [received]
PHST- 2016/06/27 00:00 [revised]
PHST- 2016/08/05 00:00 [accepted]
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2017/12/06 06:00 [medline]
PHST- 2016/08/16 06:00 [entrez]
PHST- 2017/12/01 00:00 [pmc-release]
AID - BCP13090 [pii]
AID - 10.1111/bcp.13090 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2016 Dec;82(6):1647-1659. doi: 10.1111/bcp.13090. Epub 2016 
      Oct 4.